📣 VC round data is live. Check it out!

Rapid Micro Biosystems Valuation Multiples

Discover revenue and EBITDA valuation multiples for Rapid Micro Biosystems and similar public comparables like Sedana Medical, Optiscan Imaging, SomnoMed, Outset Medical and more.

Rapid Micro Biosystems Overview

About Rapid Micro Biosystems

Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.


Founded

2006

HQ

United States

Employees

163

Financials (LTM)

Revenue: $36M
EBITDA: ($43M)

EV

$98M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Rapid Micro Biosystems Financials

Rapid Micro Biosystems reported last 12-month revenue of $36M and negative EBITDA of ($43M).

In the same LTM period, Rapid Micro Biosystems generated $6M in gross profit, ($43M) in EBITDA losses, and had net loss of ($46M).

Revenue (LTM)


Rapid Micro Biosystems P&L

In the most recent fiscal year, Rapid Micro Biosystems reported revenue of $34M and EBITDA of ($43M).

Rapid Micro Biosystems is unprofitable as of last fiscal year, with gross margin of 3%, EBITDA margin of (127%), and net margin of (140%).

See analyst estimates for Rapid Micro Biosystems
LTMLast FY202320242025202620272028
Revenue$36M$34M$23M$28M$34M
Gross Profit$6M$1M($5M)($109K)$1M
Gross Margin17%3%(24%)(0%)3%
EBITDA($43M)($43M)($53M)($47M)($43M)
EBITDA Margin(119%)(127%)(237%)(166%)(127%)
EBIT Margin(127%)(141%)(251%)(178%)(141%)
Net Profit($46M)($47M)($52M)($47M)($47M)
Net Margin(128%)(140%)(233%)(167%)(140%)

Financial data powered by Morningstar, Inc.

Rapid Micro Biosystems Stock Performance

Rapid Micro Biosystems has current market cap of $98M, and enterprise value of $98M.

Market Cap Evolution


Rapid Micro Biosystems' stock price is $1.96.

Rapid Micro Biosystems share price decreased by 2.5% in the last 30 days, and by 43.2% in the last year.

Rapid Micro Biosystems has an EPS (earnings per share) of $-0.95.

See more trading valuation data for Rapid Micro Biosystems
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$98M$98M-0.5%-2.5%-13.7%-43.2%$-0.95

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Rapid Micro Biosystems Valuation Multiples

Rapid Micro Biosystems trades at 2.7x EV/Revenue multiple, and (2.3x) EV/EBITDA.

See NTM and 2027E valuation multiples for Rapid Micro Biosystems

EV / Revenue (LTM)


Rapid Micro Biosystems Financial Valuation Multiples

As of June 3, 2026, Rapid Micro Biosystems has market cap of $98M and EV of $98M.

Rapid Micro Biosystems has a P/E ratio of (2.1x).

LTMLast FY202320242025202620272028
EV/Revenue2.7x2.9x4.4x3.5x2.9x
EV/EBITDA(2.3x)(2.3x)(1.8x)(2.1x)(2.3x)
EV/EBIT(2.1x)(2.1x)(1.7x)(2.0x)(2.1x)
EV/Gross Profit16.4x94.0x(17.9x)n/m94.0x
P/E(2.1x)(2.1x)(1.9x)(2.1x)(2.1x)
EV/FCF(2.1x)(3.1x)(2.1x)(2.2x)(3.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Rapid Micro Biosystems Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Rapid Micro Biosystems Margins & Growth Rates

Rapid Micro Biosystems grew revenue by 17% but EBITDA decreased by 4% in the last fiscal year.

In the most recent fiscal year, Rapid Micro Biosystems reported gross margin of 3%, EBITDA margin of (127%), and net margin of (140%).

See estimated margins and future growth rates for Rapid Micro Biosystems

Rapid Micro Biosystems Margins

Last FY202420252026202720282029
Gross Margin3%(0%)3%25%
EBITDA Margin(127%)(166%)(127%)(105%)
EBIT Margin(141%)(178%)(141%)(111%)
Net Margin(140%)(167%)(140%)(114%)
FCF Margin(95%)(162%)(95%)(103%)

Rapid Micro Biosystems Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth17%25%20%17%
Gross Profit Growth830%(98%)(1061%)830%
EBITDA Growth(4%)(13%)(8%)(4%)
EBIT Growth(8%)(12%)(5%)(8%)
Net Profit Growth(5%)(11%)0%(5%)
FCF Growth27%(3%)(30%)27%

Data powered by FactSet, Inc. and Morningstar, Inc.

Rapid Micro Biosystems Operational KPIs

Rapid Micro Biosystems' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.

Rapid Micro Biosystems' Rule of 40 is (88%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Rapid Micro Biosystems' Rule of X is (62%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Rapid Micro Biosystems
LTMLast FY202320242025202620272028
Rule of 40(101%)(88%)---
Bessemer Rule of X(75%)(62%)---
Revenue per Employee-$0.2M---
Opex per Employee-$0.3M---
S&M Expenses to Revenue35%36%59%47%36%
G&A Expenses to Revenue65%68%111%78%68%
R&D Expenses to Revenue38%41%57%52%41%
Opex to Revenue-144%227%178%144%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Rapid Micro Biosystems Competitors

Rapid Micro Biosystems competitors include Sedana Medical, Optiscan Imaging, SomnoMed, Outset Medical, CEL, Zomedica, Neuronetics, Cumberland, Creo Medical Group and AOTI.

Most Rapid Micro Biosystems public comparables operate across Laboratory Services, Medical Devices, HealthTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Sedana Medical4.0x4.0x(80.3x)(103.0x)
Optiscan Imaging131.0x-(21.4x)-
SomnoMed1.1x1.0x14.3x10.8x
Outset Medical0.3x0.3x(0.8x)(0.9x)
CEL(0.0x)(0.0x)(0.4x)-
Zomedica-1.9x--
Neuronetics1.2x1.2x(8.4x)(10.0x)
Cumberland1.9x-28.8x-

This data is available for Pro users. Sign up to see all Rapid Micro Biosystems competitors and their valuation data.

Start Free Trial

Rapid Micro Biosystems VC Funding History

Before going public, Rapid Micro Biosystems raised $325M in total equity funding, across 6 rounds.


Rapid Micro Biosystems Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Mar-21Undisclosed stageAdage Capital Management; BlackRock; CaaS Capital Management; D1 Capital Partners; Sunley House Capital Management; T. Rowe Price$81M-Rapid Micro Biosystems, Inc. develops data integrity and automation technology for microbial detection in biopharmaceutical manufacturing, focusing on improving quality control in biologics, vaccines, and cell & gene therapy production. The company is headquartered in Lowell, Massachusetts, with U.S. manufacturing there and global locations in Germany and the Netherlands. On March 16, 2021, it completed an $81 million equity financing round led by new investor D1 Capital Partners, with participation from BlackRock, T. Rowe Price Associates, Adage Capital Management, Sunley House Capital Management, and CaaS Capital Management. Existing investors include Bain Capital Life Sciences, Ally Bridge Group, Longitude Capital, Xeraya Capital, Endeavour Vision, Quaker Partners, and Asahi Kasei Medical. This Series D1 round brought the company's total equity raised to over $340 million. J.P. Morgan Securities LLC acted as sole placement agent. The funds were intended to continue global expansion of its automated pharmaceutical QC platform, particularly to address emerging needs in cell and gene therapies, which require intensive microbial quality control for small-batch personalized medicines. D1 Capital's analyst James Rogers highlighted the company's positioning to modernize microbial quality control and support leading pharmaceutical companies in ensuring product safety.
May-20Undisclosed stageAlly Bridge Group; Asahi Kasei Medical Europe; Bain Capital; Endeavour Vision; Longitude Capital; Xeraya Capital$120M-Rapid Micro Biosystems is a life science tools company based in Lowell, MA, providing automated, high-volume, secure microbial quality control solutions primarily for pharmaceutical manufacturing, including detection of bacterial contamination in biologics, vaccines, cell and gene therapies, sterile injectables, as well as food, beverage, personal care, environmental water, and diagnostics sectors. In April/May 2020, the company raised $120 million in an equity financing round led by Ally Bridge Group, with participation from other investors including Asahi Kasei Medical Europe, Bain Capital Life Sciences, Endeavour Vision, Longitude Capital, and Xeraya Capital. The funds were intended to support team expansion by 20% and development of a new rapid sterility consumable test. This round was part of Ally Bridge Group's broader $150 million financing across three U.S. companies amid the COVID-19 pandemic, marking ABG's first private investments in life science tools (Rapid Micro) and telehealth. Prior investors included EDBI, KPCB Holdings, Longitude Capital, Quaker Bioventures, TPG, and TVM Capital, with a 2017 Singapore financing pathway approved. The company continued growth post-round, raising an additional $81 million in March 2021 to expand its automated pharmaceutical QC platform globally, focusing on data integrity and safety in biopharma manufacturing. Rapid Micro Biosystems completed an IPO on Nasdaq in July 2021.
May-18Undisclosed stageBain Capital; Xeraya Capital$60M-Rapid Micro Biosystems, a US-based company headquartered in Lowell, Massachusetts, develops automated, growth-based rapid microbial detection technology, such as its Growth Direct system, for quality control in healthcare product manufacturing including pharmaceuticals, biologics, biotech products, medical devices, and personal care products. The technology automates traditional manual microbial testing to detect contamination faster, reducing inventory costs, shortening manufacturing cycles, minimizing product losses, improving data integrity, and enhancing operational efficiency in an industry reliant on 60-year-old methods. In early 2018, around February 5, Rapid Micro Biosystems raised $60 million in an equity financing round co-led by new investors Bain Capital Life Sciences and Xeraya Capital, with participation from new investor Asahi Kasei Medical and existing backers Longitude Capital, Quaker Partners, TVM Capital, and Richard K. Mellon and Sons. This followed a $25 million Series C in 2015 and an earlier $18.6 million Series A. The funds were allocated to accelerate global commercial expansion, build operational and supply chain capabilities, enhance product innovation including workflow improvements and upstream/downstream offerings, and increase market penetration where automated testing adoption remains low despite adoption by major pharma and biotech firms. The round positions Rapid Micro Biosystems to capitalize on growing demand for quality control automation amid efforts to prevent microbial contamination events and streamline operations. CEO Robert Spignesi highlighted the support from Bain Capital Life Sciences and Xeraya Capital for disruptive technologies in healthcare manufacturing. Investors like Jeff Schwartz from Bain noted the large market opportunity served by outdated manual processes.
Apr-15Series CHepalink; Kleiner Perkins; Longitude Capital; Quaker Partners; TPG; TVM Capital$25M-Rapid Micro Biosystems, a provider of automated, non-destructive, rapid microbial detection systems like the Growth Direct System for pharmaceutical, personal care, and medical device quality control testing, raised $25 million in Series C equity financing on April 29, 2015. The round featured new investors Hepalink USA Inc. and Richard K. Mellon and Sons, alongside existing backers Kleiner Perkins Caufield & Byers, Longitude Capital, Quaker Partners, TPG Biotech, and TVM Capital, and TPG as lead. Funds were allocated to expand global commercial and manufacturing operations to support applications in environmental monitoring, sterility, and bioburden testing following strong reception to the next-generation Growth Direct System launched the prior year. The Growth Direct System stands out as the only market solution enabling concurrent, automated quality control testing across applications on a single instrument, delivering results in hours with problem alerts for swift remediation, thereby boosting productivity, response times, and error reduction over traditional methods. CEO Robert Spignesi highlighted tremendous positive feedback from leading global pharma, personal care, and medical device firms, positioning the investment to drive strategic expansion plans. This Series C followed an earlier $18.6 million Series A with some overlapping investors like Kleiner Perkins, TVM Capital, and Quaker BioVentures, used for market expansion and product development. Subsequent financings included a $60 million equity round in 2018 led by Bain Capital Life Sciences and Xeraya Capital, and an IPO in 2021 raising $158.4 million at $20 per share.
Apr-14Series AKleiner Perkins; Longitude Capital; Quaker Partners; TPG; TVM Capital$6M--
Jun-13Series BKleiner Perkins; Longitude Capital; Quaker Partners; TPG; TVM Capital$33M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Rapid Micro Biosystems

When was Rapid Micro Biosystems founded?Rapid Micro Biosystems was founded in 2006.
Where is Rapid Micro Biosystems headquartered?Rapid Micro Biosystems is headquartered in United States.
How many employees does Rapid Micro Biosystems have?As of today, Rapid Micro Biosystems has over 163 employees.
Who is the CEO of Rapid Micro Biosystems?Rapid Micro Biosystems' CEO is Robert Spignesi.
Is Rapid Micro Biosystems publicly listed?Yes, Rapid Micro Biosystems is a public company listed on Nasdaq.
What is the stock symbol of Rapid Micro Biosystems?Rapid Micro Biosystems trades under RPID ticker.
When did Rapid Micro Biosystems go public?Rapid Micro Biosystems went public in 2021.
Who are competitors of Rapid Micro Biosystems?Rapid Micro Biosystems main competitors include Sedana Medical, Optiscan Imaging, SomnoMed, Outset Medical, CEL, Zomedica, Neuronetics, Cumberland, Creo Medical Group, AOTI.
What is the current market cap of Rapid Micro Biosystems?Rapid Micro Biosystems' current market cap is $98M.
What is the current revenue of Rapid Micro Biosystems?Rapid Micro Biosystems' last 12 months revenue is $36M.
What is the current revenue growth of Rapid Micro Biosystems?Rapid Micro Biosystems revenue growth (NTM/LTM) is 18%.
What is the current EV/Revenue multiple of Rapid Micro Biosystems?Current revenue multiple of Rapid Micro Biosystems is 2.7x.
Is Rapid Micro Biosystems profitable?No, Rapid Micro Biosystems is not profitable.
What is the current EBITDA of Rapid Micro Biosystems?Rapid Micro Biosystems has negative EBITDA and is not profitable.
What is Rapid Micro Biosystems' EBITDA margin?Rapid Micro Biosystems' last 12 months EBITDA margin is (119%).
What is the current EV/EBITDA multiple of Rapid Micro Biosystems?Current EBITDA multiple of Rapid Micro Biosystems is (2.3x).
What is the current FCF of Rapid Micro Biosystems?Rapid Micro Biosystems' last 12 months FCF is ($48M).
What is Rapid Micro Biosystems' FCF margin?Rapid Micro Biosystems' last 12 months FCF margin is (133%).
What is the current EV/FCF multiple of Rapid Micro Biosystems?Current FCF multiple of Rapid Micro Biosystems is (2.1x).
How many companies Rapid Micro Biosystems has acquired to date?Rapid Micro Biosystems hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Rapid Micro Biosystems has invested to date?Rapid Micro Biosystems hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Rapid Micro Biosystems

Lists including Rapid Micro Biosystems

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial